Common Sense Oncology shared EORTC – European Organisation for Research and Treatment of Cancer’s post on LinkedIn, adding:
“Cancer treatment delivery and outcomes are shaped by the results of clinical trials.
That’s why it’s important to ensure trials remain unbiased and focused on answering clinical questions that matter most.
EORTC – European Organisation for Research and Treatment of Cancer has published a new paper in The Lancet Oncology (The Lancet Group) today highlighting international agreement on the fundamental nature of academic clinical trials. While becoming less common in today’s research landscape, these academic trials intrinsically prevent bias.
Common Sense Oncology agrees with the Comment published in The Lancet Oncology and looks forward to the publication of the dedicated Commission.”
Quoting EORTC’s post:
“Published today: Academic clinical cancer trials to improve patient outcomes
Published in The Lancet Oncology, our latest article examines how academic research help close evidence gaps, improve real‑world care, and support equitable access to innovation.
The paper also sets the scene for further work through a forthcoming Commission on academic cancer research. Stay tuned!
With contributions from Denis Lacombe (EORTC), Winette van der Graaf and Martin Stockler.”
More posts about Common Sense Oncology.